Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) such as programmed cell death protein-1 (PD-1) inhibitors or PD-1 ligand-1 (PD-L1) inhibitors have led to remarkable improvement in outcomes of non-small cell lung cancer (NSCLC). Unfortunately, the significant benefits of ICI therapy are frequently li...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkar, Joy, Cortes Gomez, Eduardo, Oba, Takaaki, Chen, Hongbin, Dy, Grace K., Segal, Brahm H., Ernstoff, Marc S., Ito, Fumito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284636/
https://www.ncbi.nlm.nih.gov/pubmed/37350807
http://dx.doi.org/10.14740/wjon1587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284636/
https://www.ncbi.nlm.nih.gov/pubmed/37350807
http://dx.doi.org/10.14740/wjon1587

Ejemplares similares